NLS Pharmaceutics AG (NLSP)

Market Cap	6.24M
Revenue (ttm)	n/a
Net Income (ttm)	-6.60M
Shares Out	1.90M
EPS (ttm)	-6.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,232
Open	3.110
Previous Close	3.180
Day's Range	3.110 - 3.549
52-Week Range	3.000 - 29.080
Beta	-0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About NLSP

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nola...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2021
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: NLSP
• Website: https://nlspharma.com